← Back to Clinical Trials
Recruiting NCT05862779

NCT05862779 Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05862779
Status Recruiting
Phase
Sponsor Federal University of Uberlandia
Condition Sarcopenia
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-07-30
Primary Completion 2025-12

Eligibility & Interventions

Sex Female only
Min Age 60 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Placebo GroupWhey Protein + PlaceboOmega 3 + Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-07-30 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the effect of omega-3 supplementation combined with whey protein intake on lean mass and strength gains in older adults performing resistance exercise. Participants will be randomized into the 4 groups. The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin. The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin. The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil. The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein. All will perform the same exercise protocol for 12 weeks

Eligibility Criteria

Inclusion Criteria: * Postmenopausal women (at least 1 year of menstrual interruption, self-reported); * To be able to practice strength exercises; * To be able to carry out supplementation; * Do not present physical, orthopedic or cardiovascular complications that prevent the performance of physical exercises; * No history of stroke or acute myocardial infarction; * Not being a smoker and/or alcoholic; * Do not perform hormone replacement therapy; * Do not use anti-inflammatory drugs; * To have normal kidney function; * To submit a medical certificate of health that proves that the individual is able to perform exercises. Exclusion Criteria: * Do not provide the necessary information for the development of the study; * Individuals with diseases previously diagnosed and undergoing treatment, such as type II diabetes mellitus, cancer, rheumatoid arthritis, high blood pressure, dyslipidemia, cardiovascular, and kidney and/or liver diseases.

Contact & Investigator

Central Contact

Erick P de Oliveira, PhD

✉ erick_po@yahoo.com.br

📞 +5534 3225-8584

Frequently Asked Questions

Who can join the NCT05862779 clinical trial?

This trial is open to female participants only, aged 60 Years or older, up to 85 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05862779 currently recruiting?

Yes, NCT05862779 is actively recruiting participants. Contact the research team at erick_po@yahoo.com.br for enrollment information.

Where is the NCT05862779 trial being conducted?

This trial is being conducted at Uberlândia, Brazil.

Who is sponsoring the NCT05862779 clinical trial?

NCT05862779 is sponsored by Federal University of Uberlandia. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology